Clinical trials
Completed Proteinuria trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
64 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2001 | 1 |
| 2002 | 2 |
| 2003 | 2 |
| 2004 | 2 |
| 2005 | 2 |
| 2006 | 3 |
| 2007 | 4 |
| 2008 | 1 |
| 2009 | 7 |
| 2010 | 3 |
| 2011 | 6 |
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 1 |
| 2015 | 5 |
| 2016 | 4 |
| 2017 | 1 |
| 2018 | 4 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2023 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 64 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 11 |
| Mayo Clinic | 3 |
| AbbVie (prior sponsor, Abbott) | 2 |
| AstraZeneca | 2 |
| Chiesi Farmaceutici S.p.A. | 2 |
| Indiana University | 2 |
| Mallinckrodt | 2 |
| The Rogosin Institute | 2 |
| US Department of Veterans Affairs | 2 |
| University of Alabama at Birmingham | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Proteinuria | 64 |
| Kidney Diseases | 14 |
| Renal Insufficiency, Chronic | 13 |
| Diabetic Nephropathies | 12 |
| Nephrotic Syndrome | 12 |
| Glomerulosclerosis, Focal Segmental | 11 |
| Albuminuria | 6 |
| Fabry Disease | 6 |
| Hypertension | 6 |
| Glomerulonephritis | 5 |
Trials
Showing 1 to 25 of 64. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.